IFNG and neoplasm: Combination therapy with the tumor-targeted immunocytokine showed sustained NHS-IL12 localization in tumors compared to NHS-IL-12 monotherapy, which resulted in a sustained proinflammatory milieu with elevated IFNγ (Figure 3B).